Royalty Pharma
RPRX
RPRX
413 hedge funds and large institutions have $8.18B invested in Royalty Pharma in 2024 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 158 increasing their positions, 135 reducing their positions, and 50 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
3.51% more ownership
Funds ownership: 68.64% → 72.15% (+3.5%)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
6% less capital invested
Capital invested by funds: $8.7B → $8.18B (-$524M)
Holders
413
Holding in Top 10
9
Calls
$18.1M
Puts
$3.2M
Top Buyers
| 1 | +$129M | |
| 2 | +$80.2M | |
| 3 | +$73.9M | |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$42M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$31.6M |
Top Sellers
| 1 | -$52.8M | |
| 2 | -$50.7M | |
| 3 | -$49.1M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$44.1M |
| 5 |
Morgan Stanley
New York
|
-$39.4M |